High Ki‐67 expression in diffuse large B‐cell lymphoma patients with non‐germinal center subtype indicates limited survival benefit from R‐CHOP therapy

Abstract

For DLBCL patients with non-GCB DLBCL and high Ki-67 expression, the survival benefit from R-CHOP therapy is limited.